搜尋
Silence Therapeutics PLC
SLN添加自選
10.390USD
-0.110-1.05%
收盤 07/02, 13:00（美東）報價延遲15分鐘
490.76M總市值
虧損本益比TTM
關於 Silence Therapeutics PLC 公司
Silence Therapeutics plc is a global clinical-stage biotechnology company engaged in transforming people’s lives by silencing diseases through precision-engineered medicines created with proprietary siRNA (short interfering RNA) technology. The Company leverages its mRNAi GOLD platform to create siRNAs designed to precisely target and silence disease-associated genes in the liver. The Company focuses on areas of high unmet medical need with programs advancing cardiovascular disease, hematology and rare diseases. Divesiran (SLN124) is its wholly owned siRNA product candidate designed to inhibit TMPRSS6 expression in the liver. Zerlasiran is a siRNA molecule designed for the treatment of cardiovascular disease associated with elevated Lp(a), a lipoprotein in the blood. In addition to its wholly owned clinical pipeline, it has a third siRNA product candidate from its mRNAi GOLD platform in Phase I development in an undisclosed indication through its collaboration with AstraZeneca.
Silence Therapeutics PLC簡介
公司代碼SLN
公司名稱Silence Therapeutics PLC
上市日期Jan 05, 2010
CEOTooman (Craig A)
員工數量116
證券類型Depository Receipt
年結日Jan 05
公司地址72 Hammersmith Road
城市LONDON
上市交易所NASDAQ OMX - NASDAQ BASIC
國家United Kingdom
郵編W14 8TH
電話442034576900
網址https://www.silence-therapeutics.com/
公司代碼SLN
上市日期Jan 05, 2010
CEOTooman (Craig A)
Silence Therapeutics PLC公司高管
名稱
名稱/職務
職務
持股
持股變動
Mr. David Jakob (Dave) Lemus, CPA
Mr. David Jakob (Dave) Lemus, CPA
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Iain Gladstone Ross
Mr. Iain Gladstone Ross
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Dr. Steven J. Romano, M.D.
Dr. Steven J. Romano, M.D.
Executive Vice President, Chief of Research and Development Officer
Executive Vice President, Chief of Research and Development Officer
--
--
Mr. Craig A. Tooman
Mr. Craig A. Tooman
President, Chief Executive Officer, Executive Director
President, Chief Executive Officer, Executive Director
--
--
Ms. Gem Hopkins
Ms. Gem Hopkins
Head of IR and Corporate Communications
Head of IR and Corporate Communications
--
--
Ms. Rhonda Heliums
Ms. Rhonda Heliums
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
--
--
Mr. Timothy (Tim) McInerney
Mr. Timothy (Tim) McInerney
Independent Director
Independent Director
--
--
名稱
名稱/職務
職務
持股
持股變動
Mr. David Jakob (Dave) Lemus, CPA
Mr. David Jakob (Dave) Lemus, CPA
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Iain Gladstone Ross
Mr. Iain Gladstone Ross
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Dr. Steven J. Romano, M.D.
Dr. Steven J. Romano, M.D.
Executive Vice President, Chief of Research and Development Officer
Executive Vice President, Chief of Research and Development Officer
--
--
Mr. Craig A. Tooman
Mr. Craig A. Tooman
President, Chief Executive Officer, Executive Director
President, Chief Executive Officer, Executive Director
--
--
Ms. Gem Hopkins
Ms. Gem Hopkins
Head of IR and Corporate Communications
Head of IR and Corporate Communications
--
--
Ms. Rhonda Heliums
Ms. Rhonda Heliums
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
--
--
常見問題
Silence Therapeutics PLC的前五大股東是誰？
Silence Therapeutics PLC的前五大股東如下：Mr. David Jakob (Dave) Lemus, CPA
有多少機構持有Silence Therapeutics PLC(SLN)的股份？
截至2026Q1，共有147家機構持有Silence Therapeutics PLC的股份，合計持有的股份價值約為19.17M，占公司總股份的40.59% 。與2025Q4相比，機構持股有所增加，增幅為-12508865.00。